FDA Tells Patients to Stick With Diabetes Drug Linked to Cancer

Related Encyclopedia • Addison's Disease • Adenocarcinoma of the Lung and Brain Metastases • Basal Cell Carcinoma • Bladder Cancer More... Related Healthscout Videos Taking on Type One: Beating Diabetes Early Tumor Detecting App: Medicine's Next Big Thing? Powerful Combo Reducing Lymphedema Fighting Breast Cancer on Your Lunch Break More... Related Animations • Breast Self-Exam Video • Colon Cancer • Diabetes More... Related Drug Information • Actonel • Actos • Amaryl • Avandamet More... Related News Articles • Smoking May Up Cancer Risk in Barrett's Esophagus Patients • Prostate Size May Be Clue to Severity of Cancer • Young Adults Who Quit Smoking Feel Better Quickly • Chemo During Pregnancy Doesn't Seem to Harm Baby More...

Page:  << Prev | 1 | 2

The FDA says it is "currently reviewing many sources of safety data for Lantus," including completed and ongoing observational and clinical trials, and may ask Sanofi to conduct further trials should they be deemed necessary.

According to the Wall Street Journal, a spokesman for Sanofi said that the company is working with the FDA on this issue and continues to stand behind the drug's safety.

In the meantime, the FDA says it "encourages both health care professionals and patients to report side effects from the use of insulin glargine to the FDA's MedWatch Adverse Event Reporting Program."

Text Continues Below

---

More information

Find out more about diabetes at the American Diabetes Association.

Page:  << Prev | 1 | 2

-- E.J. Mundell